These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25980593)

  • 1. Lymphangioleiomyomatosis: New Treatment Perspectives.
    Radzikowska E
    Lung; 2015 Aug; 193(4):467-75. PubMed ID: 25980593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphangioleiomyomatosis: Current understanding and potential treatments.
    Moir LM
    Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
    El-Chemaly S; Goldberg HJ; Glanville AR
    Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
    Yates DH
    Expert Rev Respir Med; 2016; 10(3):249-60. PubMed ID: 26847859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
    Yu J; Parkhitko AA; Henske EP
    Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.
    Glasgow CG; Steagall WK; Taveira-Dasilva A; Pacheco-Rodriguez G; Cai X; El-Chemaly S; Moses M; Darling T; Moss J
    Respir Med; 2010 Jul; 104 Suppl 1(Suppl 1):S45-58. PubMed ID: 20630348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing treatments for lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    Expert Rev Respir Med; 2012 Jun; 6(3):267-76. PubMed ID: 22788941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
    Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
    Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
    Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
    Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    F1000Prime Rep; 2014; 6():116. PubMed ID: 25580270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
    Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
    Goncharova EA; Krymskaya VP
    J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis.
    Bottolo L; Miller S; Johnson SR
    Thorax; 2020 Aug; 75(8):679-688. PubMed ID: 32467337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pulmonary lymphangioleiomyomatosis: From pathogenesis to management].
    Chebib N; Khouatra C; Lazor R; Archer F; Leroux C; Gamondes D; Thivolet-Bejui F; Cordier JF; Cottin V
    Rev Mal Respir; 2016 Oct; 33(8):718-734. PubMed ID: 26604019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    Clin Epidemiol; 2015; 7():249-57. PubMed ID: 25897262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphangioleiomyomatosis.
    Doubková M; Štefániková M; Čan V; Merta Z; Svoboda M
    Klin Onkol; 2019; 32(5):367-374. PubMed ID: 31610670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
    Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
    Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR signaling in lymphangioleiomyomatosis.
    Kristof AS
    Lymphat Res Biol; 2010 Mar; 8(1):33-42. PubMed ID: 20235885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphatic involvement in lymphangioleiomyomatosis.
    Glasgow CG; Taveira-Dasilva AM; Darling TN; Moss J
    Ann N Y Acad Sci; 2008; 1131():206-14. PubMed ID: 18519973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.